Abstract:Objectives: Long-term hepatitis B virus (HBV) infection can cause recurrent inflammation in the liver, and then develop into liver fibrosis, cirrhosis, and liver cancer. The hepatic pathological change is one of the important criteria for guiding antiviral therapy in patients with chronic hepatitis B (CHB). Due to the limitations of liver biopsy, it is necessary to find valuable non-invasive indicators to evaluate the hepatic pathological changes in CHB patients and guide the antiviral therapy. This study aims to analyze the clinical characteristics of different pathological changes in CHB patients, and to explore the factors influnencing the degree of liver inflammation and fibrosis in CHB patients with normal alanine aminotransferase (ALT). Methods: This retrospective study was conducted on 310 CHB patients. Liver biopsy was performed in all these patients. The clinical data of the patients were collected. The liver biopsy pathological results were used as the gold standard to analyze the relationship between clinical indicators and liver pathological changes. Then CHB patients with normal ALT were screened, and the independent factors influencing the degree of liver inflammation and fibrosis were explored. Results: Among the 310 patients with CHB, there were 249 (80.3%) patients with significant liver inflammation [liver inflammation grade (G) ≥2] and 119 (38.4%) patients with significant liver fibrosis [liver fibrosis stage (S) ≥2]. The results of univariate analysis of total samples showed that the ALT, γ-glutamyl transferase, alkaline phosphatase, and HBV DNA were related to the significant liver pathological changes. Among the 132 CHB patients with normal ALT, the patients with liver pathology G/S≥2, G≥2, and S≥2 were 80.3% (106/132), 68.2% (90/132), and 43.2% (57/132), respectively. The results showed that the independent influencing factor of significant liver inflammation was HBV DNA>2 000 U/mL (OR=3.592, 95% CI 1.534 to 8.409), and the independent influencing factors of significant liver fibrosis were elevated alkaline phosphatase level (OR=1.022, 95% CI 1.002 to 1.043), decreased platelet count (OR=0.990, 95% CI 0.982 to 0.998), and positive in hepatitis B e antigen (HBeAg) (OR=14.845, 95% CI 4.898 to 44.995). According to the multivariate analysis, a diagnostic model for significant liver fibrosis in CHB patients with normal ALT was established, and the area under the receiver operating characteristic curve was 0.844 (95% CI 0.779 to 0.910). Conclusions: The liver pathological changes should be evaluated in combination with different clinical indicators. A considerable number of CHB patients with normal ALT still have significant liver pathological changes, which need to be identified and treated with antiviral therapy in time. Among them, HBV DNA>2 000 U/mL suggests the significant liver inflammation, and the diagnostic model for significant liver fibrosis based on alkaline phosphatase, platelet count, and HBeAg can help to evaluate the degree of liver fibrosis.

Clinical value of serum biochemical markers and changes of T lymphocyte subsets in patients with liver cirrhosis after having AIDS and hepatitis B

Analysis on Clinical Features and Immunity in Chronic Hepatitis B Virus Infected Patients with Low-Level Hbsag

Efficacy of different therapeutic modalities for patients with acute-on-chronic liver failure induced by hepatitis B

[Highly Active Antiretroviral Therapy on Liver Function in HIV-positive Children with HBV/HCV Co-Infection].

The Clinical Significance of the Change of Blood-Lipid in Patients with Hepatitis B-related Cirrhosis.

Changes of the peripheral Thelper cell cytokines of patients with chronic hepatitis B during antiviral treatment

Change and Significance of T cell subsets chronic HBV infected patients

HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients

Changes of peripheral blood lymphocyte subsets absolute values in hepatitis B patients

Predictive Value of Serum ALT and T-cell Receptor Beta Variable Chain for HBeAg Seroconversion in Chronic Hepatitis B Patients During Tenofovir Treatment

HBsAg Levels in HBeAg-positive Chronic Hepatitis B Patients with Different Immune Conditions.

Biological characteristics and survival analysis in HIV/HCV co-infected patients

Clinicopathologic characteristics of liver inflammation and fibrosis in 310 patients with chronic hepatitis B

Changes of immunoglobulin, sP-selectin and sICAM-1 in patients with different degrees of hepatitis b cirrhosis and the possible clinical significance

Characteristics of T-cell subsets and serum cytokines in patients with chronic hepatitis B during different immune status and after antivirus treatment

[Liver Histological Changes in Chronic Hepatitis B Patients with Elevated ALT Less Than 2 X ULN].

Clinical significance of liver biopsy in the diagnosis of liver disease and the evaluation of the clinical efficacy of antiviral treatment for chronic hepatitis B

Significant Histologic Changes Are Not Rare in Treatment-naive Hepatitis B Patients with Normal Alanine Aminotransferase Level: A Meta-analysis.

Significance and Change of Serum Cytokines and T Lymphocyte Subsets in Peripheral Blood in Patients with Primary Biliary Cirrhosis

Efficacy of Antiviral Treatment in Liver Biopsy-Proven Immune-Tolerant Chronic Hepatitis B Patients: A Retrospective Cohort Study

Clinical features of patients with HBeAg-negative chronic hepatitis B and HBV-related cirrhosis